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Abstract
Halloysite is aluminosilicate clay with a hollow tubular structure with nanoscale internal and 
external diameters. Assessment of halloysite biocompatibility has gained importance in view of its 
potential application in oral drug delivery. To investigate the effect of halloysite nanotubes on an 
in vitro model of the large intestine, Caco-2/HT29-MTX cells in monolayer co-culture were 
exposed to nanotubes for toxicity tests and proteomic analysis. Results indicate that halloysite 
exhibits a high degree of biocompatibility characterized by an absence of cytotoxicity, in spite of 
elevated pro-inflammatory cytokine release. Exposure-specific changes in expression were 
observed among 4081 proteins analyzed. Bioinformatic analysis of differentially expressed protein 
profiles suggest that halloysite stimulates processes related to cell growth and proliferation, subtle 
responses to cell infection, irritation and injury, enhanced antioxidant capability, and an overall 
adaptive response to exposure. These potentially relevant functional effects warrant further 
investigation in in vivo models and suggest that chronic or bolus occupational exposure to 
halloysite nanotubes may have unintended outcomes.
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Introduction
Halloysite is natural aluminosilicate clay with a hollow tubular structure that enables loading 
and sustained release of biomacromolecules and drugs. The nanotubes are about 0.5–2 μm 
long with a 10–20 nm inner luminal diameter and can be loaded with saturated solutions of 
proteins, DNA, antibiotics and other drugs drawn into the tubes by capillary forces (Joussein 
et al., 2005; Price et al., 2001; Shchukin et al., 2005). This enables long-term bioavailability 
of drugs (ciprofloxacin, gentamicin and tetracycline) and microbial antiseptics (iodine, 
brilliant green and amoxicillin). The surface of halloysite nanotubes is silicon oxide that is 
considered a biocompatible material. However, more detailed studies of halloysite clay 
toxicity are necessary to demonstrate its suitability for drug delivery formulations.
Halloysite biomedical applications include its use for stem cell attachment, cancer cell 
isolation, bone implants, teeth fillers, cosmetics and controlled drug delivery (Hughes and 
King, 2010; Kelly et al., 2004; Kommireddy et al., 2006; Veerabadran et al., 2007; Vergaro 
et al., 2012; Wei et al., 2012). The first published paper on halloysite use as a nanocontainer 
demonstrated 10–20 h sustained release of tetracycline, khellin and NAD (Price et al., 2001), 
and was followed by multiple publications on halloysite controlled drug release. Halloysite 
functionalized with selectin protein was used as target-specific coatings to capture leukemic 
and epithelial cancer cells (Hughes and King, 2010). Intracellular uptake by cells of different 
origins (cervical adenocarcinoma or breast cancer cells) and cytoviability tests demonstrated 
relative halloysite cytocompatibility and potential as a bio-friendly cargo nanocontainer for 
biomaterials (Vergaro et al., 2010). In that previous study, cell viability decreased to 80% of 
the control after exposure to 500 μg ml–1 halloysite (a very high concentration of c. 4 × 108 
nanotubes per ml). Those clay nanotubes were further modified through: (i) increased lumen 
diameter resulting in an increased drug loading capacity up to 30–40%; and (ii) 
encapsulation of the clay tubes in organic polymeric shells with tube-end stoppers resulting 
in increased control over the release kinetics of loaded drugs in the range of 20–100 h 
(Abdullayev et al., 2012). Halloysite clay has been considered to be 
a ’green‘ environmentally safe material, and the nanotubes are available in tons from natural 
deposits.
Because halloysite nanotubes are being considered for oral drug delivery (Forsgren et al., 
2010; Kawakami et al., 2012; Suresh et al., 2010), it is critical to assess their potential 
gastrointestinal effects. Besides the study mentioned above, few in vitro studies have 
examined the effects of halloysite exposure, and those that did demonstrated variable 
effects, including significant declines in viability in Hela (cervical) and MCF-7 (breast) 
cancer cell lines (Vergaro et al., 2012) after 24 h, but no effect on 3T3 (fibroblast) cells over 
48 h (Suh et al., 2011). To provide a culture system more relevant to halloysite ingestion, the 
present study used a well-characterized in vitro Caco-2/HT29-MTX co-culture model 
simulating the large intestine. Caco-2 and HT29-MTX adenocarcinoma cell lines are derived 
from intestinal absorptive and mucus-secreting goblet cell (Lesuffleur et al., 1991) types, 
respectively. Their combination provides a physiologically relevant co-culture system 
characterized by tight junctions and considerable mucus secretion (Hilgendorf et al., 2000; 
Mahler et al., 2009a, 2009b; Walter et al., 1996) that covers the entire monolayer. We have 
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recently used this model to study the effects of carbon nanotube exposure (Lai et al., 2013), 
and that paper illustrates the distinct polarization and tight-junction formation achieved in 
the current investigation.
Using this co-culture model, cytotoxic and proinflammatory end-point assays, and an 
innovative, label-free quantitative mass spectrometric (LFQMS) platform recently 
developed in our laboratory (Lai et al., 2011), we present significant effects of halloysite 
exposure on cellular protein expression, in the absence of overt toxicity, and link these 
changes to specific pathways and molecular functions that have physiological relevance. 
This represents the first investigation of halloysite effects on intestinal epithelial cells in 
vitro, providing novel evidence regarding the inflammatory and functional effects of 
halloysite clay nanotubes on the intestinal barrier.
Materials and Methods
Reagents and Nanoparticles
DL-Dithiothreitol (DTT), urea, triethylphosphine, iodoethanol and ammonium bicarbonate 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). LC-MS grade 0.1% formic acid 
in acetonitrile and 0.1% formic acid in water were purchased from Burdick & Jackson 
(Muskegon, MI, USA). Modified sequencing grade porcine trypsin was obtained from 
Princeton Separations (Freehold, NJ, USA). Halloysite clay powder was obtained from 
Applied Minerals Inc., NY, USA and used without further purification. It contained 95% 
halloysite clay nanotubes and the remaining few percent were kaolin and silica (see Table 
1).
Characterization of Halloysite Nanotubes
Halloysite samples were mixed with ethanol and sonicated in a water bath (Branson, 
Danbury, CT, USA) for 10–15 min until well dispersed. For each sample, a droplet of the 
suspension was placed on a copper grid and dried at room temperature. Transmission 
electron microscopy imaging and energy dispersive spectroscopy (EDS) elemental analysis 
were performed using a Hitachi HD 2000 STEM. The zeta potential of the suspended 
halloysite in water was measured using electrophoretic light scattering (ZetaSizer Nano; 
Malvern Instruments, Malvern, Worcestershire, United Kingdom). A 1-mg sample of the 
halloysite clay nanotubes was analyzed for the presence of endotoxin by nanoComposix 
(San Diego, CA, USA Malvern, Worcestershire WR14 1XZ United Kingdom) using the 
kinetic turbidity Limulus Amebocyte Lysate (LAL) assay.
Cell Culture and Exposures
Caco-2, human colorectal adenocarcinoma cells (ATCC HTB-37, Lot 57863838) were 
maintained in Eagle's minimal essential medium (EMEM) supplemented with 10% fetal 
bovine serum (FBS) (ATCC catalog numbers 30-2003 & 30-2020) and incubated at 37 °C – 
5% CO2. HT29-MTX, human colon adenocarcinoma cells treated with methotrexate 
(Lesuffleur et al., 1993), were obtained from Dr Thécla Lesuffleur (INSERM, Paris, France) 
and were maintained in Dulbecco's Modified Eagle's Medium (DMEM) with glutamax and 
10% heat inactivated FBS (Invitrogen, Carlsbad CA, USA) at 37 °C – 5% CO2. Both cell 
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lines were sub-cultured at 80–90% confluence. Caco-2 (passage 45) and HT29-MTX cells 
(passage 29) were cultured to obtain several Corning T75 flasks. At 80–90% confluence, the 
cells were trypsinized and the flasks were pooled. Cells were counted using a 
hemocytometer and then mixed together at a 75: 25 Caco-2 to HT29-MTX ratio and placed 
in the HT29-MTX medium with 1% penicillin-streptomycin. Combined cells were 
mechanically mixed and 1.5 mL was added to six-well Transwell™ inserts to obtain 0.4 × 
106 cells per well (8.9 × 104 cells per cm2) (Hilgendorf et al., 2000).
Cells were incubated at 37 °C – 5% CO2 for 14 days prior to exposure, replacing the 
medium every other day, to achieve full, post-confluent differentiation, polarization and 
tight-junction formation. Halloysite clay nanotubes were weighed and added to autoclavable 
glass tubes with screw caps; water was added to make a 5 mg ml–1 suspension. Prior to cell 
exposure, the halloysite suspension was sonicated in a water bath sonicator for 5 min and 
vortexed for 20–30 s. Immediately, a 160-μl aliquot was diluted in 3.84 ml of HT29-MTX 
medium (DMEM) to a final concentration of 200 μg ml–1. This stock was then diluted to 
exposure concentrations of 1, 10 and 100 μg ml–1. These halloysite doses were chosen to 
correspond to those used in a previous study (Vergaro et al., 2010).
The final halloysite mixtures were gently sonicated, vortexed quickly and 1.5 ml placed in 
the top (apical) compartment of the six Transwell™ plate containing the co-cultured cells, as 
depicted in Fig. 1. The bottom (basolateral) compartment contained 2.5 ml of fresh medium.
Control groups received only fresh medium in both compartments. The treated cells were 
incubated for 6 h at 37 °C – 5% CO2. This exposure duration was used to simulate the 
transient nature of gastrointestinal exposure to ingested nanotubes. The authors acknowledge 
that this short time frame of exposure may not have captured the potential cytotoxicity that 
might have been better assessed at a later time point. To assess the cell number at exposure, 
replicate co-cultured cells were trypsinized and counted using a hemocytometer (n = 4) after 
14 days. Cell counts indicated a total of ~750 000 cells per Transwell™ insert.
Cell Viability, Membrane Integrity and Permeability Assays
In assays that produce insoluble formazan dyes (such as the MTT assay), NTs can attach to 
the insoluble MTT formazan product disrupting the distinguishing, colorimetric reaction 
(Worle-Knirsch et al., 2006). Therefore, assays that produce soluble dyes such as XTT are 
preferred. Accordingly, cell viability was determined using the Cell Proliferation Kit 
(Roche, Indianapolis, IN, USA) according to manufacturer's instructions. Membrane leakage 
of LDH into the apical media from potentially damaged or dead cells was assessed using the 
CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, Fitchburg, WI, USA) according 
to the manufacturer's instructions. Apically applied Triton™ X-100 treatment (0.05%) was 
included as a positive control and barrier function was assessed by measuring unidirectional 
paracellular flux of Lucifer yellow from the apical to basolateral compartments. This assay 
was conducted via the Lucifer Yellow Permeability Assay (BD Biosciences, Franklin Lakes, 
NJ, USA) according to the manufacturer's instructions, using Transwell™ cultures as 
described above.
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Chemokine/Cytokine Analysis
To determine the level of irritation or proinflammatory response associated with halloysite 
exposure after 6 h, cell culture medium was collected from apical and basolateral 
compartments of the Transwell™ plates and evaluated for the following chemokines: 
monocyte chemotactic protein-1 (MCP-1), a proinflammatory cytokine produced and 
released in response to various stimuli, such as bacterial invasion and interleukin-8 (IL-8) 
another proinflammatory chemokine. In addition, granulocyte macrophage-colony-
stimulating factor (GM-CSF), a cytokine that amplifies an inflammatory response and 
promotes tissue repair and tumor necrosis factor-alpha (TNF-α), a prominent component of 
intestinal proinflammatory activities were evaluated. Assays were carried out by enzyme-
linked immunosorbent assay (ELISA) Quantikine Colorimetric kits (R&D Systems, Inc., 
Minneapolis, MN, USA) according to the manufacturer's instructions. All four of these 
chemokines/cytokines are known to be expressed constitutively by intestinal epithelial cells 
(Jung et al., 1995) as substantiated by the Gene Expression Omnibus (GEO) database (Edgar 
et al., 2002), which stores individual gene expression profiles from curated data sets in its 
repository. Group means for cell viability, membrane integrity, permeability and chemokine/
cytokine analyses were compared by one-way ANOVA using post hoc pairwise multiple 
comparisons [Holm–Sidak method (Holm, 1979)].
Proteomics and Bioinformatic Analysis
After incubation of the exposed cells, the media from both compartments were individually 
removed, placed into separate labeled microfuge tubes, snap frozen in liquid nitrogen and 
placed on dry ice until transfer to a -80°C freezer for cytokine analysis. The Transwell™ 
membranes containing adherent cells were quickly rinsed 3 times in ice-cold 250 mM 
sucrose, snap frozen in liquid nitrogen, placed on dry ice and then stored at –80°C. For 
Caco-2/HT29-MTX lysate preparation for LFQMS, 500 μl of lysis buffer (8 M urea, 10 mM 
DTT, freshly prepared) was added to each sample. All cells were incubated at 35 °C for 1 h 
with agitation and transferred to a test tube. Cell lysates were centrifuged at 15 000 g for 20 
min at 4 °C to remove insoluble materials and the supernatant transferred to a new tube. 
Fully solubilized cell protein samples were then stored at –80°C until LFQMS analysis.
Protein concentration was determined using the Bradford Protein Assay using Bio-Rad 
(Hercules, CA, USA) protein assay dye reagent concentrate. An aliquot containing 100 μg of 
each cell lysate sample was adjusted to 200 μl with 4 M urea and then reduced and alkylated 
by triethylphosphine and iodoethanol, as described previously (Lai et al., 2008). A 150-μl 
aliquot of a 20 μg ml–1 trypsin solution was added to the sample and incubated at 35 °C for 
3 h, after which another 150 μl of trypsin was added, and the solution incubated at 35 °C for 
3 h (n = 5 per observation). Exactly 20 μg of each tryptic digest sample (n = 5) were injected 
randomly as two technical replicates onto a C18 reversed phase column (TSK gel 
ODS-100V, 3 μm, 1.0 × 150 mm) at a flow rate of 50 μl min–1 as part of the Surveyor 
autosampler and MS HPLC system (Thermo-Electron, Waltham, MA, USA) coupled to a 
Thermo-Finnigan linear ion-trap (LTQ) mass spectrometer. The mobile phases A and B 
were 0.1% formic acid in water and 50% ACN with 0.1% formic acid in water, respectively. 
The gradient elution profile was as follows: 10% B (90% A) for 7 min and 10–67.1% B (90–
32.9% A) for 163 min, 67.1–100% B (32.9–0% A) for 10 min. The spectral data were 
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collected in the ’data dependent MS/MS‘ mode with the ESI interface using a normalized 
collision energy of 35%. Dynamic exclusion settings were repeat count 1, repeat duration 30 
s, exclusion duration 120 s and exclusion mass width 0.6 m/z (low) and 1.6 m/z (high). A 
blank was injected between each sample to clean and balance the column and to eliminate 
carryover. The acquired data were searched against the International Protein Index (IPI) 
database (ipi.HUMAN.v3.83) using SEQUEST (v. 28 rev. 12) algorithms in Bioworks (v. 
3.3). General parameters were set to: peptide tolerance 2.0 amu, fragment ion tolerance 1.0 
amu, enzyme limits set as ’fully enzymatic – cleaves at both ends’ and missed cleavage sites 
set at 2. Peptide and protein identifications were validated by PeptideProphet (Keller et al., 
2002) and ProteinProphet (Nesvizhskii et al., 2003) in the Trans-Proteomic Pipeline (TPP, v. 
3.3.0; http://tools.proteomecenter.org/software.php). Only proteins with a probability ≥ 
0.9000 and peptides with a probability ≥ 0.8000 were reported. Protein abundance was 
determined using IdentiQuantXL™ (Lai et al., 2011). Briefly, after chromatogram alignment 
and peptide retention time determination, a weighted mean m/z of each peptide was 
calculated and a tab delimited file was created to extract peptide intensity using MASIC 
(Monroe et al., 2008). Peptides were then filtered according to intensity coefficients of 
variation (CV) across all samples and intensity correlation, for those identifying a particular 
protein. Protein abundance was then calculated from all qualified corresponding peptides 
matched to that protein.
Comparison of the abundance of individual protein dose-group means generated by LFQMS 
was performed within the IdentiQuantXL™ platform using one-way ANOVA and Pairwise 
Multiple Comparisons (Holm–Sidak method). The critical F-ratio significance for ANOVA 
was set at P < 0.01 and a pairwise comparison at P < 0.05. The False Discovery Rate (FDR) 
(Storey, 2002) was estimated using Q-value software. To interpret the biological relevance 
of the differential protein expression data and to compare biological effects across different 
halloysite exposure levels, protein lists and their corresponding expression values (fold 
change) were uploaded onto the Ingenuity Pathway Analysis (IPA) software server (http://
www.ingenuity.com) and analyzed using the Core Analysis module to rank the proteins into 
top biological functions and canonical pathways, and to discover upstream regulators that 
may explain the observed differential protein expression.
Results
Characterization of Halloysite Nanotubes
The nanotubes used in this study ranged from 0.2–2.0 μm in length and 50–100 nm in outer 
diameter (Table 1 and Fig. 2A, B). The lumen diameter was 10–20 nm such that its volume 
comprises 15–20% of the total nanotube volume. Periodicity in the individual layer packing 
determined with X-ray analysis is 0.72 nm, which corresponds to the dehydrated halloysite. 
The Brunauer–Emmett–Teller (BET) surface area of the halloysite is 50 ± 4 m2/g1.
Results from the elemental analysis of energy dispersive spectra also confirmed an 
abundance of oxygen, aluminum and silicon in the halloysite nanotubes (Table 1). The 
hydrodynamic sizes of the halloysite tubes dispersed in water at pH 6.5 is in the range 250–
300 nm (effective diameter corresponding to the 3D radius of gyration of elongated particle 
gives kind of average size). Halloysite zeta potential in water (Table 1) was –42.6 mV, thus 
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confirming that electrochemical behavior of halloysite in water has a similarity with silica 
nanoparticles. The outer surface of these clay nanotubes consists of SiO2 and the innermost 
lumen surface is Al2O3. At pH range 4-9, the nanotube's aluminal interior is positively 
charged whereas the tube's outside surface, relevant to silica, is negatively charged. Zeta 
potential analysis of the culture media was non-determinant owing to screening of the 
nanotubes by constituent ions and biomolecules.
Endotoxin analysis revealed a level of 0.01885 EU ml–1, permitting us to eliminate this as a 
factor that may have influenced the results.
Cell Viability, Membrane Integrity and Permeability Assays
Halloysite exposure for 6 h had no effect at any concentration on cell viability, membrane 
integrity as measured by LDH leakage or barrier permeability (Fig. 3). Membrane integrity 
was disrupted only in the Triton™ X-100-treated positive control, as expected.
Chemokine/Cytokine Analysis—As illustrated in Fig. 4, the secretion of several 
chemokines and cytokines into both apical and basolateral media was altered by halloysite 
exposure. While the chemokine MCP-1 was unaffected, IL-8 was significantly elevated by 
the 100 μg ml–1 exposure in the apical (luminal) and by all three halloysite concentrations in 
basolateral (interstitial) media (1.5-fold at 10 μg ml–1). In contrast, with GM-CSF and TNF-
α, polarized secretion was clearly evident with halloysite exposure. GM-CSF secretion was 
significantly reduced by 3.5-fold in the apical media by the 1 μg ml–1 exposure and 
significantly elevated in the basolateral media at 10 and 100 μg ml–1. TNF-α secretion in the 
apical media was elevated by all exposures, maximally at nearly 10-fold by the 10 μg ml–1 
exposure, whereas secretion on the basolateral side was significantly reduced by all 
exposures.
Proteomics—LFQMS analysis identified and quantified 4081 non-redundant Caco-2/
HT29-MTX proteins. These are unique database hits representing individual proteins, splice 
variants, or isoforms whose relative abundance ranged across five orders of magnitude. A 
complete list of these proteins along with mass spectral data including identification 
parameters and group mean quantities/statistics is presented in Table S1. Of the 4081 
proteins analyzed, significant quantitative expression changes as a result of halloysite 
exposure were observed in 473. Lists of proteins altered by each exposure (1, 10 and 100 μg 
ml–1) along with their quantitation data can be found in Tables S2–4. The average CV for 
control, 1, 10 and 100 μg ml–1 groups was 21.4%, 13.9%, 18.3% and 11.9%, respectively. In 
the 100 μg ml–1 group, 3137 proteins had a CV < 15%.
As illustrated graphically in Fig. 5A and C, 100 μg ml–1 halloysite exposure significantly 
altered the expression of 415 proteins, 404 of which were up-regulated. In contrast, the 1 
and 10 μg ml–1 exposures altered the expression of only 67 and 60 proteins, respectively. At 
1 μg ml–1, 35 proteins were up-regulated and 32 were down-regulated, whereas 46 were up-
regulated and only 14 were down-regulated at 10 μg ml–1. Table 2 shows the top 10 protein 
fold differences (both up- and down-regulation) at each exposure (P < 0.05). These lists 
indicate that the greatest fold-changes in expression were +2.1 [histone-lysine N-
methyltransferase (MLL)] and -2.6 WD repeat-containing protein 66 (WDR66), whereas 
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most were considerably less, and all demonstrate that the halloysite effects on differential 
protein expression were moderate, in spite of their statistical significance.
Bioinformatics—Given the heterogeneity of differential expression and lack of overlap 
across halloysite exposures, to get a better understanding of the biological effects of the 
protein changes, we conducted a bioinformatic analysis of the protein alteration profiles 
associated with each exposure using Ingenuity Pathway Analysis. This assessment enabled 
us to identify the top (i) biological functions and their predicted activation states (Table 3), 
(ii) canonical pathways (Table 4) and (iii) upstream regulators (Table 5) that were associated 
with differentially expressed proteins in a statistically significant manner and relevant to 
barrier epithelia.
Discussion
The cell viability, membrane integrity and permeability assay results are consistent with 
previous observations where only long-term (> 24 h) exposure to nanoclays decreased the 
viability of Hela and MCF-7 (Vergaro et al., 2010), HepG2 (Lordan et al., 2011), and 
another study where Cloisite (R) Na(+) nanoclay cytotoxicity was absent in human 
monocytic U937 cells when nanoparticles were coated with FBS (Lordan and 
Higginbotham, 2012), an effect attributed to greater dispersibility. Similarly, Li et al. (2010) 
observed minor cytotoxicity of Cloisite nanoclay in Chinese hamster ovary cells below 1000 
μg ml–1 after 12-h exposures, and a dose-dependent effect after 24-h incubation. In general, 
it seems that at low doses, nanoclay has low cytotoxicity. When toxic effects are observed, 
they are related to clay nanotube functionalization or compounds filling them (Sharma et al., 
2010; Shi et al., 2011; Vergaro et al., 2012; Zapor and Dzierzawska, 2012).
In general, nanoparticles exert proinflammatory effects in lung and immune tissues that is 
characterized by, at least in part, increased cytokine/chemokine production (Chang, 2010; 
Shannahan et al., 2012a). However, exposure of intestinal epithelia to nanomaterials in vitro 
has been shown to have little effect on proinflammatory cytokine release (Bergin and 
Witzmann, 2012), and in a previous study using this co-culture system (Lai et al., 2013), 
altered cytokine release in response to functionalized carbon nanotube exposure up to 10 μg 
ml–1 was negligible, in spite of significant changes in cellular protein expression. 
Proinflammatory effects of halloysite exposure have not been reported, nor does it appear 
that such consequences have been investigated in intestinal cells. In contrast, halloysite has 
been shown to exert anti-inflammatory effects in murine primary peritoneal macrophages in 
vitro (Cornejo-Garrido et al., 2012) and allergic inflammation in vivo in mice (Park et al., 
2008). Alternatively, bacterial infection of enterocytes is known to cause the polarized, 
basolateral secretion of the cytokines measured in this study (Jung et al., 1995), especially 
IL-8 (Laurent et al., 1997) or both IL-8 and MCP-1 (Kim et al., 2002). Typical bacilli are 
rod shaped and are about 2.0 μm long and 500 nm in diameter, somewhat similar to the 
range of halloysite dimensions used in this study. As bioinformatic analysis of differential 
expression shows (see below), proteins linked to cell infection were up-regulated by the 100 
μg ml–1 exposure. Together, these observations suggest that the intestinal cells may respond 
to halloysite as if infected by bacteria. Although the halloysite nanotube interaction with the 
apical membrane and potential internalization is beyond the scope of the present study, 
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much larger, high-aspect ratio nanoparticles, such as multi-walled carbon nanotubes, do not 
seem to enter enterocytes in culture (Clark et al., 2011; Lai et al., 2013), so it is possible the 
same is true for the halloysite nanotubes. This notion warrants further study.
As halloysite exposure concentration increased, up-regulation of specific proteins also 
increased, while protein down-regulation was ameliorated. This suggests unique cellular 
effects at these different exposures and infers the development of an adaptive, cytoprotective 
generalized stress response (Osburn and Kensler, 2008) (see below in Upstream Regulators 
section) with an increasing halloysite concentration. For instance, five proteins commonly 
associated with cell stress were significantly up-regulated only at 100 μg ml–1, heat shock 
factor-binding protein 1, activator of 90-kDa heat shock protein ATPase, heat shock 70-kDa 
proteins 4 and 7, and heat-shock protein 105 kDa.
In terms of overall impact, compared with the 100 μg ml–1 exposure that altered the 
expression of over 10% of the proteins analyzed, halloysite exposures that were one and two 
orders of magnitude lower had a comparatively little effect. The notion of differential dose-
related protein regulation is further supported by the Venn diagram, Fig. 5B, which 
illustrates the discernible scarcity of overlap in those proteins whose expression was altered 
by each exposure. Only two proteins, brain-specific angiogenesis inhibitor 1-associated 
protein 2-like protein 1 (BAIAP2L1) and eukaryotic translation initiation factor 4 gamma 2 
(EIF4G2), were common to all three exposures, and all three were moderately up-regulated. 
BAIAP2L1 [also known as insulin receptor tyrosine kinase substrate (IRTKS)] is a 
ubiquitously expressed protein involved in the formation of clusters of actin bundles 
(Millard et al., 2007), is known to be up-regulated in inflammatory conditions (Galligan et 
al., 2007) and plays a role in the reorganization of the actin cytoskeleton in response to 
bacterial infection (Vingadassalom et al., 2009). EIF4G2, another ubiquitous protein, is also 
known as death-associated protein 5 (DAP-5) and p97. This protein is abundantly expressed 
in proliferating cells and is recruited to ribosomes after growth factor stimulation to promote 
protein synthesis and cell proliferation (Lee and McCormick, 2006). In contrast, inducible 
expression of EIF4G2 (p97) has been shown to reduce overall protein synthesis by acting as 
a general repressor of translation (Imataka et al., 1997). Its moderate up-regulation at all 
exposures may reflect similar responses with different cellular outcomes in the enterocytes 
at different levels of halloysite nanoclay exposure. Both BAIAP2L1 and EIF4G2 have been 
shown to be up-regulated in HT29 cells undergoing endoplasmic reticular stress (Saito et al., 
2009), one facet of an adaptive response. Of those proteins undergoing the greatest fold 
change, histone-lysine N-methyltransferase (MLL) mediates the methylation of ’Lys-4’ of 
histone H3 (H3K4me), a specific tag for epigenetic transcriptional activation (Ansari et al., 
2009). Histone H3 lysine 4 methylation generally correlates with active transcriptional 
expression (Santos-Rosa et al., 2002), so the two-fold increase in MLL expression may 
signify higher transcriptional activity at 100 μg ml–1, which may be related to the observed 
up-regulation of 404 proteins at this exposure.
Consistent with the overall lack of overlap across exposure groups, only two differentially 
expressed proteins appeared in more than one exposure, phosphoglucomutase-2 (PGM2) and 
signal recognition particle 14 kDa protein (SRP14), which were down-regulated by 1 and 
100 μg ml–1 halloysite exposures. Also known as phosphopentomutase, PGM2 participates 
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in the pentose phosphate pathway and in purine metabolism by catalyzing the conversion of 
the nucleoside breakdown products ribose-1-phosphate and deoxyribose-1-phosphate to the 
corresponding 5-phosphopentoses. SRP14 is a component of the signal recognition particle 
(SRP) assembly that targets secretory proteins to the rough endoplasmic reticulum 
membrane (Lütcke, 1995). The SRP is composed of SRP9, SRP14, SRP19, SRP54, SRP68 
and SRP72 (Walter and Blobel, 1980), where SRP9 and SRP14 are required for RNS 
binding. All six of these SRP components were identified and quantified in this study, 
including the signal recognition particle receptor subunit alpha. However, only SRP9 and 
SRP14 were differentially expressed, and surprisingly, SRP9 was up-regulated by 1 and 100 
μg ml–1 halloysite exposures, compared with SRP14's down-regulation.
With respect to biological functions associated with differential expression, proteins whose 
expression was altered by the 1 μg ml–1 halloysite exposure failed to associate significantly 
with any increased or decreased activation states. Proteins altered by the 10 μg ml–1 
exposure were associated with ’proliferation of tumor cell lines‘, a result consistent with the 
cell viability data. Proteins altered by the 100 μg ml–1 exposure were associated 
with ’infection of cells‘ (32 proteins) and ’viral infection of cells‘ (55 proteins) along with 9 
other functional annotations variably associated with increased ’cell growth and 
proliferation‘ and ’cellular assembly and organization’. These latter annotations include 
increased activation states in nucleotide hydrolysis and cytokinesis, both emblematic of 
growth (‘growth of organism‘) and cell division.
Activation of lamellipodia (filopodia) formation in colon cancer cells increases their 
migratory and invasive properties (Makrodouli et al., 2011) and is associated with 
significant cytoskeletal (actin) rearrangement (Khurana et al., 2008). However, it is also an 
important cell migration mechanism in wound healing in intestinal epithelia (Arciero et al., 
2011). Whether this response to high-dose halloysite exposure reflects actual injury, which 
our cytotoxicity data do not support, or related to the use of cancer cells in the in vitro model 
requires additional study. The fact that activation states associated with cell infection were 
increased and mapped to a significant number of proteins, suggests that an injury response, 
or at least an irritation response (based on IL-8 and TNF-α responses in Fig. 4), may have 
been underway at 6 h. Perhaps the halloysite size and shape, along with its protein corona 
(Shannahan et al., 2012b), may elicit such a broad response in the Caco-2/HT29-MTX cells 
under these conditions. This speculation requires additional investigation. Nevertheless, in 
terms of biological function, a significant response by the intestinal cell-lines in co-culture 
to 100 μg ml–1 halloysite exposure is clear, whereas the low doses had little effect, if any, in 
this regard.
Canonical pathway analysis detected no significant associations at the 2 lowest exposures. 
However, proteins altered by 100 μg ml–1 halloysite exposure mapped to 9 pathways, all of 
which were up-regulated. Three of these pathways, glutathione redox reactions II, ascorbate 
recycling and the thioredoxin pathway, represent an interrelated antioxidant system in which 
the component enzymes are capable of regenerating several antioxidant compounds, 
including ascorbic acid, as well as reducing oxidized proteins and reactive oxygen species 
(ROS) (Nordberg and Arnér, 2001). Serine biosynthesis pathway up-regulation is consistent 
with enhanced cell growth and proliferation suggested by the biological function analysis.
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The ’lipid antigen presentation by CD1‘ pathway was mapped (P < 0.0005) by 4 up-
regulated proteins. The expression and extracellular presentation of lipid antigens to immune 
cells (e.g. T cells) by CD1 molecules in intestinal cells may play a role in natural host 
defense against bacterial colonization and invasion at the mucosal barrier (Dougan et al., 
2007; Sugita et al., 2000). Up-regulation of components of this pathway may relate to 
the ’cell infection‘ function activated by halloysite exposure and alluded to earlier.
Ingenuity Pathway Analysis was used to predict which upstream regulators may have been 
activated or inhibited by halloysite exposure and to help explain the bioactivity of halloysite 
nanotubes in the Caco-2/HT29-MTX co-culture system. In this case, ’upstream 
regulator‘ refers to any molecule that can affect the expression of a protein or set of related 
proteins in a regulatory pathway, including transcription factors, cytokines, microRNAs, 
receptors and kinases. Neither the 1 nor 10 μg ml–1 exposures resulted in the identification 
of upstream regulators that were significantly related to differentially expressed proteins. 
However, proteins whose expression was altered by 100 μg ml–1 halloysite nanotube 
exposure were mapped to 10 different upstream regulators, 7 of which were predicted to be 
activated and 3 inhibited.
Activated regulators included the antioxidant transcription factor NFE2L2 (nuclear factor 
erythroid 2-related factor 2 or Nrf2), a transcription activator that binds to antioxidant 
response elements in the promoter regions of target genes (Itoh et al., 1997) and is involved 
in the coordinated up-regulation of genes in response to oxidative stress in the intestine 
(McMahon et al., 2001) and a generalized cytoprotective adaptive response to toxic insult 
(Osburn and Kensler, 2008). Several of the activated regulators are associated with cell 
growth and proliferation. For instance, in contrast to antioxidant response, NFE2L2 is also 
associated closely with increased cell growth (Ohta et al., 2008). Two other growth-related 
factors, MYC and TGFB1 also were identified.
In terms of upstream regulators with inhibited activation states, 3 microRNAs were 
identified and protein alterations mapped to them that suggested their activity was inhibited 
by 100 μg ml–1 halloysite exposure. These included miR-124-3p, miR-1 and miR-155-5p. 
MicroRNAs (miRNAs) are key posttranscriptional regulators of gene expression involved in 
diverse biological pathways, acting through translational repression, mRNA decay, or both 
(Lee and Shin, 2012). Assessment of miRNA responses to nanoparticle exposure in 
mammalian or human systems has not yet been reported, nor have indirect methods such as 
we present here been used previously. Our protein profiles suggest that nanoparticle 
exposure may act through altered expression of these novel regulators and should be taken 
into account in future studies.
The present investigation was conducted to examine the effect of halloysite clay nanotube 
exposure and represents the first investigation of halloysite effects on intestinal barrier 
epithelia in co-culture in vitro. The major new findings of this study include: (i) significant 
proinflammatory effects at halloysite exposures as low as 1 μg ml–1 and (ii) significant 
changes in protein expression at 100 μg ml–1. Based on these findings, halloysite clay 
nanotubes appear unlikely to have toxic effects at moderate levels of exposure. However, 
significant exposure-specific changes in expression were observed among the 4081 proteins 
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analyzed, particularly at the high concentration. Bioinformatic analysis of differentially 
expressed protein profiles generated by 100 μg ml–1 exposure suggest that halloysite 
stimulates processes related to cell growth and proliferation, subtle responses to cell 
infection, irritation and injury, enhanced antioxidant capability, all characteristic of an 
overall adaptive response to exposure. These potentially relevant functional effects warrant 
further investigation in both in vitro and in vivo models and suggest that chronic or high 
concentration bolus exposure to halloysite nanotubes might have unintended outcomes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Caco-2/HT29-MTX intestinal cell co-culture system for modeling gastrointestinal halloysite 
exposure.
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Figure 2. 
Transmission electron microscopic images of two different concentrations of the halloysite 
nanotubes used in this investigation, confirming their moderately high aspect ratio, 
dimension range and hollow interior.
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Figure 3. 
Effect of halloysite exposure on Caco-2/HT29-MTX cells: cell viability after 6 h determined 
by the XTT assay; membrane integrity (LDH leakage) after 6 h determined by the CytoTox 
96 assay. Triton X-100 was included as a positive control. ANOVA P < 0.001, *post-hoc 
Holm–Sidak P < 0.001 vs. halloysite expoures and control; and epithelial barrier integrity 
(apical to basolateral compartment paracellular permeability) after 6 h determined by the 
Lucifer Yellow assay. All values in the three graphs are means ± standard deviation (SD) for 
n = 5, with optical densities normalized to the control.
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Figure 4. 
Effect of 6-h halloysite exposure on mean ± standard deviation (SD) cytokine release (n = 5) 
by the Caco-2/HT29-MTX cells into apical (AP) and basolateral (BL) media compartments. 
The y-axis in each graph represent fold-differences when ELISA results are normalized to 
Control group values. *P < 0.05 based on post-hoc pairwise multiple comparisons (Holm–
Sidak method) after ANOVA, NS, not significant.
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Figure 5. 
Caco-2/HT29-MTX protein expression data determined by label-free quantitative mass 
spectrometry: (A) bar graphs illustrating the number of proteins up-regulated (red) and 
down-regulated (blue) by each halloysite exposure. (B) Venn diagram illustrating the lack of 
overlap in differentially expressed proteins across the three exposures. (C) Volcano plots of 
all 4081 proteins identified and quantified, illustrating their magnitude, significance, and 
direction of differential expression observed at each halloysite exposure. The horizontal red 
line in each graph signifies P < 0.05.
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Table 1
Physicochemical properties of halloysite clay nanotubes
Outer diameter (nm) 50–100
Inner diameter (nm) 10–20
Length (μm) 0.2–2.0
Zeta potential (mV) –42.6
C content (atomic %) 6.74
N content (atomic %) 1.25
O content (atomic %) 50.17
Al content (atomic %) 20.33
Si content (atomic %) 19.25
Ca content (atomic %) 0.10
Fe content (atomic %) 0.69
Cu content (atomic %) 1.47
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Table 2
Ten most halloysite-mediated up- and down-regulated Caco-2/HT29-MTX cell proteins (P < 0.05) based on 
fold-difference
Fold 1 μg m l–1 Fold 10 μg m l–1 Fold 100 μg m l–1
1.6 Structural maintenance of 
chromosomes protein
1.7 Methylosome subunit pICIn 2.1 Histone-lysine N-methyltransferase, 
isoform 1
1.5 Eukaryotic translation initiation 
factor 4 gamma 2
1.6 Laminin subunit beta-1 1.8 Chromatin target of PRMT1 protein, 
isoform 1
1.4 Chromatin accessibility complex 
protein 1
1.5 Eukaryotic translation initiation factor 4 gamma 
2
1.8 5′-AMP-activated protein kinase 
subunit gamma-1
1.4 D-tyrosyl-tRNA(Tyr) deacylase 1 1.5 Keratin 25D 1.7 Low MW phosphotyrosine protein 
phosphatase
1.4 High mobility group protein B3 1.4 Dynein light chain Tctex-type 1 1.7 Protein KIAA1967 (Deleted in breast 
cancer gene 1 protein)
1.4 Protein transport protein Sec61 
subunit alpha
1.4 Mitogen-activated protein kinase 14, isoform 
CSBP2
1.7 StAR-related lipid transfer protein 10
1.4 Signal recognition particle 9 kDa 
protein
1.4 Phosphate carrier protein, mitochondrial, isoform 
A
1.7 Alcohol dehydrogenase class-3
1.4 Tudor domain-containing protein 1 1.3 60S ribosomal protein L19 1.6 ADP-ribosylation factor 6
1.3 Centrosomal protein 110kDa 1.3 6-phosphogluconolactonase 1.6 Calpain-9, isoform 1
1.3 Copine-1 1.3 Brain-specific angiogenesis inhibitor 1-
associated protein
1.6 HLA class II histocompatibility 
antigen, DRalpha chain
-1.6 Serine/threonine-protein 
phosphatase 2A
-2.6 WD repeat-containing protein 66 -1.5 Putative PDZ domain-containing 
protein 1P
-1.5 Polyhomeotic 2 homolog -1.9 60S ribosomal protein L9 -1.4 Signal recognition particle 14 kDa 
protein
-1.5 PDZ domain-containing protein 1P -1.6 FACT complex subunit SSRP1 -1.3 Serum paraoxonase/arylesterase 2, 
isoform 1
-1.5 Eukaryotic translation initiation 
factor 1
-1.4 26S proteasome non-ATPase regulatory subunit -1.3 Phosphoglucomutase-2
-1.4 U6 snRNA-associated Sm-like 
protein LSm3
12-1.3 Mucin-17 -1.3 ATP-dependent RNA helicase 
DHX40, isoform 1
-1.4 Polymerase I and transcript release 
factor
-1.3 Erlin-2 -1.3 Coiled-coil domain-containing 
protein 120
-1.4 Phosphoglucomutase-2 -1.3 ADP-ribosylation factor GTPase-activating 
protein 2
-1.2 PDZ and LIM domain protein 5
-1.4 BH3-interacting domain death 
agonist
-1.2 Vesicular integral-membrane protein VIP36 -1.2 Cadherin-2
-1.3 Syntaxin-binding protein 3 -1.2 Serine/threonine-protein kinase ULK1 -1.2 Arsenical pump-driving ATPase
-1.3 Signal recognition particle 14 kDa 
protein
-1.2 Glucosamine-6-phosphate isomerase -1.2 Cytochrome b5 reductase 3
Gray-shaded proteins are altered by more than one exposure.
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Table 4
Top canonical pathways mapped* to differentially expressed Caco-2/HT29-MTX cell proteins
Exposure Canonical pathway -log (P-value) % of pathway 
mapped
Proteins
1 μg ml–1 NA NA NA NA
10 μg ml–1 NA NA NA NA
100 μg ml–1 Glutathione redox reactions II 3.45 100% GSR▲, TXNDC12▲, GLRX▲
Ascorbate recycling (cytosolic) 2.98 67% GLRX▲, GSTO1▲
Serine biosynthesis 2.68 50% PSAT1▲, PSPH▲
2-ketoglutarate dehydrogenase complex 2.68 40% DLST▲, DLD▲
UDP-N-acetyl-D-galactosamine biosynthesis II 3.46 33% GNPNAT1▲, GALE▲, UAP1▲
Thioredoxin Pathway 2.47 33% TXN▲, TXNRD1▲
UDP-N-acetyl-D-glucosamine biosynthesis II 2.30 33% GNPNAT1▲, UAP1▲
Granzyme B signaling 3.73 25% NUMA1▲, CYCS▲, LMNB1▲, 
DFFA▲
Lipid antigen presentation by CD1 3.33 20% CALR▲, ARF6▲, CANX▲, AP2A2▲
*Only those pathways significantly (P < 0.01) mapped to at least two proteins representing ≥ 20% of pathway protein constituents are listed. NA, 
not applicable.
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